Oncogene Protein v-akt

"Oncogene Protein v-akt" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A viral oncoprotein originally isolated from a murine T CELL LYMPHOMA infected with the acutely transforming retrovirus AKT8. v-akt protein is the viral homologue of PROTO-ONCOGENE PROTEINS C-AKT.

Descriptor ID	D051058
MeSH Number(s)	D08.811.913.696.620.682.700.586 D12.776.624.664.520.750.788
Concept/Terms	Oncogene Protein v-akt Oncogene Protein v-akt Oncogene Protein v akt v-akt, Oncogene Protein v-akt Protein v-akt Kinase Transforming Protein v akt Kinase Transforming Protein akt-Oncogene Protein akt Oncogene Protein Oncogene Protein akt akt, Oncogene Protein

Below are MeSH descriptors whose meaning is more general than "Oncogene Protein v-akt".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Serine-Threonine Kinases [D08.811.913.696.620.682.700]
Oncogene Protein v-akt [D08.811.913.696.620.682.700.586]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Neoplasm Proteins [D12.776.624]
Oncogene Proteins [D12.776.624.664]
Oncogene Proteins, Viral [D12.776.624.664.520]
Retroviridae Proteins, Oncogenic [D12.776.624.664.520.750]
Oncogene Protein v-akt [D12.776.624.664.520.750.788]

Below are MeSH descriptors whose meaning is related to "Oncogene Protein v-akt".

Below are MeSH descriptors whose meaning is more specific than "Oncogene Protein v-akt".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Oncogene Protein v-akt" by people in this website by year, and whether "Oncogene Protein v-akt" was a major or minor topic of these publications.

Bar chart showing 11 publications over 8 distinct years, with a maximum of 2 publications in 2006 and 2007 and 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	0	1	1
2006	2	0	2
2007	0	2	2
2010	1	1	2
2011	0	1	1
2012	0	1	1
2016	0	1	1
2021	1	0	1

Below are the most recent publications written about "Oncogene Protein v-akt" by people in Profiles.

Schneider M, Dillinger AE, Ohlmann A, Iozzo RV, Fuchshofer R. Decorin-An Antagonist of TGF-? in Astrocytes of the Optic Nerve. Int J Mol Sci. 2021 Jul 17; 22(14).

View in: PubMed
Butchbach MER, Lumpkin CJ, Harris AW, Saieva L, Edwards JD, Workman E, Simard LR, Pellizzoni L, Burghes AHM. Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy. Exp Neurol. 2016 May; 279:13-26.

View in: PubMed
Chow HY, Jubb AM, Koch JN, Jaffer ZM, Stepanova D, Campbell DA, Duron SG, O'Farrell M, Cai KQ, Klein-Szanto AJ, Gutkind JS, Hoeflich KP, Chernoff J. p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Res. 2012 Nov 15; 72(22):5966-75.

View in: PubMed
Inge LJ, Barwe SP, D'Ambrosio J, Gopal J, Lu K, Ryazantsev S, Rajasekaran SA, Rajasekaran AK. Soluble E-cadherin promotes cell survival by activating epidermal growth factor receptor. Exp Cell Res. 2011 Apr 01; 317(6):838-48.

View in: PubMed
Keefe SM, Cohen MA, Brose MS. Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. Clin Cancer Res. 2010 Feb 01; 16(3):778-83.

View in: PubMed
Altomare DA, Zhang L, Deng J, Di Cristofano A, Klein-Szanto AJ, Kumar R, Testa JR. GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt. Clin Cancer Res. 2010 Jan 15; 16(2):486-96.

View in: PubMed
Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G, Larson S, Schwartz L, Egorin MJ, Rosen N, Scher HI. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res. 2007 Mar 15; 13(6):1775-82.

View in: PubMed
Gavi S, Yin D, Shumay E, Wang HY, Malbon CC. Insulin-like growth factor-I provokes functional antagonism and internalization of beta1-adrenergic receptors. Endocrinology. 2007 Jun; 148(6):2653-62.

View in: PubMed
Oyama K, Okawa T, Nakagawa H, Takaoka M, Andl CD, Kim SH, Klein-Szanto A, Diehl JA, Herlyn M, El-Deiry W, Rustgi AK. AKT induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture. Oncogene. 2007 Apr 05; 26(16):2353-64.

View in: PubMed
Narayan P, Holt B, Tosti R, Kane LP. CARMA1 is required for Akt-mediated NF-kappaB activation in T cells. Mol Cell Biol. 2006 Mar; 26(6):2327-36.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement